These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 19601995

  • 1. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 2. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.
    AIDS; 2009 Sep 10; 23(14):1829-40. PubMed ID: 19474650
    [Abstract] [Full Text] [Related]

  • 3. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
    Antivir Ther; 2011 Sep 10; 16(1):99-108. PubMed ID: 21311113
    [Abstract] [Full Text] [Related]

  • 4. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.
    J Clin Virol; 2007 Feb 10; 38(2):131-8. PubMed ID: 17208042
    [Abstract] [Full Text] [Related]

  • 5. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.
    AIDS; 2009 Aug 24; 23(13):1679-88. PubMed ID: 19487905
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.
    AIDS; 2008 Jul 31; 22(12):1389-97. PubMed ID: 18614861
    [Abstract] [Full Text] [Related]

  • 7. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.
    HIV Med; 2013 Jan 31; 14(1):49-59. PubMed ID: 23088336
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.
    Antivir Ther; 2004 Aug 31; 9(4):595-602. PubMed ID: 15456091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM, TMC114-C226 study group, ARCA study group.
    Antivir Ther; 2011 Aug 31; 16(4):489-97. PubMed ID: 21685536
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A, Mauskopf J, Talbird SE, Smets E.
    Pharmacoeconomics; 2010 Aug 31; 28 Suppl 1():129-46. PubMed ID: 21182348
    [Abstract] [Full Text] [Related]

  • 18. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.
    AIDS; 2010 Jan 16; 24(2):223-30. PubMed ID: 20010070
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.